Compare Sanofi SA (SNY) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Zillow Group Inc Class C — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Zillow Group Inc Class C trades at $29.01 (market cap $6.59B). The key difference: Sanofi SA is far larger — about 14.4× Zillow Group Inc Class C's market cap, and Sanofi SA pays a 6.01% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Zillow Group Inc Class C for 38 Days on average.
| SNY | Z | |
|---|---|---|
Market Cap | $95.18B | $6.59B |
Volume | 2,995,646 | 9,134,294 |
Sector | Health | Media |
52-Week High | $52.34 | $78.04 |
52-Week Low | $39.51 | $27.13 |
Typical Hold Time | 94 Days | 38 Days |
Enterprise Value | $114.48B | $6.47B |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Zillow Group (Z) trades at $29.01, up 6.34% in the past 24 hours, showing strong momentum despite mixed technical signals. The company demonstrates improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability with $23M net income. Recent earnings show two consecutive beats against expectations, though the stock faces headwinds from elevated mortgage rates and housing market volatility.
The outlook remains cautiously optimistic with analyst consensus price target of $60.33 suggesting significant upside potential. However, investors face risks from housing market sensitivity to interest rates and competitive pressures. The company's transition to an integrated transaction platform and AI integration present growth opportunities, but execution risks and market conditions warrant careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
